ZA200207093B - Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids. - Google Patents
Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids. Download PDFInfo
- Publication number
- ZA200207093B ZA200207093B ZA200207093A ZA200207093A ZA200207093B ZA 200207093 B ZA200207093 B ZA 200207093B ZA 200207093 A ZA200207093 A ZA 200207093A ZA 200207093 A ZA200207093 A ZA 200207093A ZA 200207093 B ZA200207093 B ZA 200207093B
- Authority
- ZA
- South Africa
- Prior art keywords
- nucleic acid
- protein
- rotavirus
- acid sequence
- virus
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 40
- 239000002245 particle Substances 0.000 title claims description 35
- 241000702670 Rotavirus Species 0.000 title claims description 25
- 108090000623 proteins and genes Proteins 0.000 title claims description 23
- 102000004169 proteins and genes Human genes 0.000 title claims description 22
- 108020004707 nucleic acids Proteins 0.000 title claims description 15
- 102000039446 nucleic acids Human genes 0.000 title claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 101710081079 Minor spike protein H Proteins 0.000 claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 24
- 102000037865 fusion proteins Human genes 0.000 claims description 24
- 108020001507 fusion proteins Proteins 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 241000283690 Bos taurus Species 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 230000000890 antigenic effect Effects 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 241000238631 Hexapoda Species 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 108700031314 Rotavirus VP6 Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000000234 capsid Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 108700015125 Adenovirus DBP Proteins 0.000 description 1
- 241001469183 Avian rotavirus PO-13 Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000773151 Homo sapiens Thioredoxin-like protein 4B Proteins 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- 101800001509 Large capsid protein Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101000667310 Macrovipera lebetina Venom serine proteinase-like protein 2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000702665 Porcine rotavirus Species 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101900236200 Rabies virus Nucleoprotein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010072659 Rotavirus NSP3 protein Proteins 0.000 description 1
- 241000702677 Simian rotavirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010064833 guanylyltransferase Proteins 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12323—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Seasonings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0002892A FR2806087B1 (fr) | 2000-03-07 | 2000-03-07 | Particules pseudovirales de rotavirus et leur utilisation pour vectoriser des proteines ou des acides nucleiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200207093B true ZA200207093B (en) | 2003-10-14 |
Family
ID=8847799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200207093A ZA200207093B (en) | 2000-03-07 | 2002-09-04 | Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20030175301A1 (de) |
| EP (1) | EP1261629B1 (de) |
| AT (1) | ATE344278T1 (de) |
| AU (2) | AU2001239350B2 (de) |
| CA (1) | CA2403029A1 (de) |
| DE (1) | DE60124230D1 (de) |
| FR (1) | FR2806087B1 (de) |
| NZ (1) | NZ521355A (de) |
| WO (1) | WO2001066566A2 (de) |
| ZA (1) | ZA200207093B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1349571A4 (de) * | 2000-11-03 | 2005-02-16 | Baylor College Medicine | Rotavirus-enterotoxin nsp4 und verfahren zu seiner verwendung |
| ES2217967B1 (es) * | 2003-03-31 | 2006-01-01 | Consejo Sup. Investig. Cientificas | Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv. |
| ES2307345B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
| ES2307346B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
| FR2865404A1 (fr) * | 2004-01-27 | 2005-07-29 | Prevendia | Composition comprenant des immunoglobulines specifiques du rotavirus |
| EP1576877A1 (de) * | 2004-03-04 | 2005-09-21 | Bioprotein Technologies | Herstellung von rekombinante Proteine aus Rotaviren in der Milch von nicht-menschlische transgenische Tiere |
| WO2006007555A2 (en) * | 2004-07-01 | 2006-01-19 | Children's Medical Center Corporation ¨ | Rotavirus antigens |
| ES2310062B1 (es) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| EP2847324B1 (de) * | 2012-05-11 | 2018-01-03 | Medicago Inc. | Produktion virusähnlicher partikel in pflanzen |
| CN103667199B (zh) | 2012-09-20 | 2019-01-22 | 厦门大学 | 体外制备轮状病毒双层类病毒颗粒的方法 |
| CN107208072A (zh) | 2015-01-23 | 2017-09-26 | 莫迪卡戈公司 | 在植物中产生轮状病毒样颗粒 |
| CN111265660B (zh) * | 2020-01-19 | 2022-11-15 | 青岛明勤生物科技有限公司 | 一种通用型疫苗免疫增强剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374426A (en) * | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| US5667782A (en) * | 1992-07-16 | 1997-09-16 | Oxford University | Multiple particulate antigen delivery system |
| US6589529B1 (en) * | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
-
2000
- 2000-03-07 FR FR0002892A patent/FR2806087B1/fr not_active Expired - Fee Related
-
2001
- 2001-03-07 NZ NZ521355A patent/NZ521355A/en not_active Application Discontinuation
- 2001-03-07 DE DE60124230T patent/DE60124230D1/de not_active Expired - Lifetime
- 2001-03-07 WO PCT/FR2001/000676 patent/WO2001066566A2/fr active IP Right Grant
- 2001-03-07 EP EP01913946A patent/EP1261629B1/de not_active Expired - Lifetime
- 2001-03-07 AU AU2001239350A patent/AU2001239350B2/en not_active Ceased
- 2001-03-07 US US10/220,267 patent/US20030175301A1/en not_active Abandoned
- 2001-03-07 AU AU3935001A patent/AU3935001A/xx active Pending
- 2001-03-07 CA CA002403029A patent/CA2403029A1/fr not_active Abandoned
- 2001-03-07 AT AT01913946T patent/ATE344278T1/de not_active IP Right Cessation
-
2002
- 2002-09-04 ZA ZA200207093A patent/ZA200207093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3935001A (en) | 2001-09-17 |
| CA2403029A1 (fr) | 2001-09-13 |
| NZ521355A (en) | 2005-04-29 |
| WO2001066566A3 (fr) | 2002-04-04 |
| EP1261629A2 (de) | 2002-12-04 |
| ATE344278T1 (de) | 2006-11-15 |
| WO2001066566A2 (fr) | 2001-09-13 |
| FR2806087A1 (fr) | 2001-09-14 |
| US20030175301A1 (en) | 2003-09-18 |
| FR2806087B1 (fr) | 2002-10-18 |
| AU2001239350B2 (en) | 2005-11-03 |
| DE60124230D1 (de) | 2006-12-14 |
| EP1261629B1 (de) | 2006-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zeltins | Construction and characterization of virus-like particles: a review | |
| ES2371833T3 (es) | Partículas quiméricas vacías similares a virus derivadas del virus de la enfermedad de la bursitis infecciosa (ibdv), proceso para su producción y aplicaciones. | |
| Teunissen et al. | Production and biomedical applications of virus-like particles derived from polyomaviruses | |
| Pumpens et al. | Artificial genes for chimeric virus-like particles | |
| EP1706486B1 (de) | Chimärische leere capside des ibdv (infectious bursal disease virus), gewinnungsverfahren und anwendungen | |
| ZA200207093B (en) | Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids. | |
| US20140178482A1 (en) | Method of producing virus-like particles of picornavirus using a small-ubiquitin-related modifier fusion protein expression system | |
| DK2288618T3 (en) | CHEMICAL FUSION PROTEINS AND VIRUS LIKE PARTICLES FROM BIRNAVIRUS VP2 | |
| CN112625095A (zh) | 一种猪轮状病毒重组蛋白以及表达该蛋白的重组腺病毒和应用 | |
| Santoni et al. | Plant virus nanoparticles for vaccine applications | |
| Grasso et al. | Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches | |
| Ignacio Casal | Use of the baculovirus expression system for the generation of virus-like particles | |
| CN114276969A (zh) | 一种SARS-CoV-2细菌样颗粒及其在疫苗中的应用 | |
| CN114423868B (zh) | 用于将大载量基因和蛋白质递送到人细胞中的原核-真核杂交病毒载体 | |
| Voronkova et al. | Chimeric bacteriophage fr virus-like particles harboring the immunodominant C-terminal region of hamster polyomavirus VP1 induce a strong VP1-specific antibody response in rabbits and mice | |
| WO2002088339A2 (fr) | Particules pseudovirales de birnavirus | |
| Mellid-Carballal et al. | Viral protein nanoparticles (Part 1): Pharmaceutical characteristics | |
| Roy et al. | Assembly of macromolecular complexes in bacterial and baculovirus expression systems | |
| WO2012007557A1 (en) | Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions | |
| Fender | Recombinant adenoviruses and adenovirus penton vectors: from DNA transfer to direct protein delivery into cell | |
| CN116789847A (zh) | 融合蛋白、病毒样颗粒以及疫苗 | |
| Berardi | An Investigation into the Use of a Plant-Expressed Virus-Like Particle as an Oral Vaccine Candidate | |
| Schenck et al. | Expression of human papilloma virus type 16 antigens, specific targeting as well as formation of virus-like particles by HSV-1 amplicon vectors |